Corvus Pharmaceuticals (NASDAQ:CRVS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the stock. Separately, Mizuho restated a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Thursday, March […]

Related Keywords

,Corvus Pharmaceuticals Company Profile ,Institutional Investors Weigh In On Corvus Pharmaceuticals ,Corvus Pharmaceuticals Inc ,Morgan Stanley ,News Ratings For Corvus Pharmaceuticals Daily ,Corvus Pharmaceuticals ,Bailard Inc ,Corvus Pharmaceuticals Price Performance ,Acadian Asset Management ,Get Rating ,Street Corp ,Asset Management ,Two Sigma Investments ,Sigma Investments ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Initiated Coverage ,Stocknews Com ,